Technical Analysis for VYGR - Voyager Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 18.02 -2.12% -0.39
VYGR closed down 2.59 percent on Tuesday, March 19, 2019, on 81 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Flat
See historical VYGR trend table...

Date Alert Name Type % Chg
Mar 19 Calm After Storm Range Contraction -2.12%
Mar 19 Wide Bands Range Expansion -2.12%
Mar 19 Overbought Stochastic Strength -2.12%
Mar 18 Jack-in-the-Box Bullish Bullish Swing Setup -4.66%
Mar 18 Inside Day Range Contraction -4.66%
Mar 18 Wide Bands Range Expansion -4.66%
Mar 18 Overbought Stochastic Strength -4.66%
Mar 15 180 Bullish Setup Bullish Swing Setup -8.34%
Mar 15 Expansion Breakout Bullish Swing Setup -8.34%
Mar 15 Pocket Pivot Bullish Swing Setup -8.34%

Older signals for VYGR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system (CNS). The company focuses in the field of adeno-associated virus gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease; and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich's ataxia, and VY-HTT01 for Huntington's disease, as well as VY-SMN101 for neuromuscular disease. The company has strategic collaborations with Genzyme Corporation and the University of Massachusetts Medical School. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Medicine Health Manufacturing Gene Therapy Genetics Parkinson's Disease Amyotrophic Lateral Sclerosis Huntington's Disease Treatment Of Parkinson's Disease Sanofi Friedreich's Ataxia Severe Diseases
Is VYGR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 24.24
52 Week Low 7.76
Average Volume 583,500
200-Day Moving Average 15.5892
50-Day Moving Average 12.3334
20-Day Moving Average 16.2565
10-Day Moving Average 17.981
Average True Range 1.0906
ADX 60.52
+DI 40.7615
-DI 10.182
Chandelier Exit (Long, 3 ATRs ) 16.5582
Chandelier Exit (Short, 3 ATRs ) 13.7718
Upper Bollinger Band 21.2788
Lower Bollinger Band 11.2342
Percent B (%b) 0.71
BandWidth 61.788208
MACD Line 1.92
MACD Signal Line 1.876
MACD Histogram 0.044
Fundamentals Value
Market Cap 495.28 Million
Num Shares 26.9 Million
EPS -2.31
Price-to-Earnings (P/E) Ratio -7.97
Price-to-Sales 69.72
Price-to-Book 5.32
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.96
Resistance 3 (R3) 20.02 19.56 19.70
Resistance 2 (R2) 19.56 19.17 19.53 19.62
Resistance 1 (R1) 18.99 18.92 18.76 18.93 19.53
Pivot Point 18.53 18.53 18.41 18.50 18.53
Support 1 (S1) 17.95 18.13 17.72 17.89 17.29
Support 2 (S2) 17.49 17.89 17.46 17.20
Support 3 (S3) 16.92 17.49 17.12
Support 4 (S4) 16.86